Corteva Inc (CTVA) Stock Forecast & Price Target

Corteva is viewed favorably because its crop protection portfolio, including herbicides, insecticides, fungicides, biologicals, and plant health products, is supported by a solid pipeline and strong biologics franchise that can offset a still-challenging ag backdrop. The company’s new products are expected to add about $800M in annual revenue by 2029 versus 2026, while biologics sales of roughly $550M in 2026E and targeted cost savings of another $200M should help lift EBITDA toward the top of the $1.45B-$1.65B range. Corteva is also attractive because shares trade near 6.5x-6.7x EV/EBITDA, unlevered FCF yield is about 10%, and a projected $0.5B net cash position by end-2026 provides flexibility for buybacks, M&A, and continued investment.

Corteva is facing a difficult crop-chemicals backdrop, with management already assuming a 1% annual price decline during the 2027-2029 period amid persistent generic pressure, limited volume growth, and weak farm economics. Its operating mix also leaves it exposed to regional softness, as North America contributes 37% of revenue and Brazil-facing demand is pressured by poor current economics, lower input consumption, and the risk of adverse weather. The negative outlook is further reinforced by slower expected monetization of the pipeline, reduced bundling power after the seed business spin-off, and roughly $450M of future cash outflows tied to water-related settlements and claims.